RECRUITING

Molecular Epidemiology of Pediatric Germ Cell Tumors

Description

A Non-Therapeutic Study that aims to establish a cohort of GCT survivors to understand short term and long-term adverse effects of treatment and to conduct molecular analyses to improve risk stratification.

Conditions

Germ Cell TumorGerminomaTeratomaEmbryonal CarcinomaYolk Sac TumorChoriocarcinomaMixed Germ Cell TumorLate EffectsPediatric Germ Cell Tumor
Talk to us

Related Conditions:

Germ Cell TumorGerminomaTeratomaEmbryonal CarcinomaYolk Sac TumorChoriocarcinomaMixed Germ Cell TumorLate EffectsPediatric Germ Cell Tumor

Study Overview

On this page

Study Details

Study overview

A Non-Therapeutic Study that aims to establish a cohort of GCT survivors to understand short term and long-term adverse effects of treatment and to conduct molecular analyses to improve risk stratification.

Pediatric Germ Cell Tumors: Outcomes, Genomics and Epigenetics

Molecular Epidemiology of Pediatric Germ Cell Tumors

Condition
Germ Cell Tumor
Intervention / Treatment

-

Contacts and Locations

Minneapolis

University of Minnesota, Minneapolis, Minnesota, United States, 55455

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Cases will be eligible for the study if they have a primary diagnosis of GCT including germinoma (ICCC code105 9060-9065), teratoma (9080-9084), embryonal carcinoma (9070-9072), yolk sac tumor (9071), choriocarcinoma (9100, 9103, 9104), and mixed GCT (9085, 9101, 9102, 9105) in all sites including the brain.
  • * The patient must be enrolled on APEC14B1 with consent to future contact or enrolled in AEPI10N1 with consent for future contact (N=827). Patients enrolled in AEPI10N1 were recruited from ACCRN07. All patients must be registered with COG by a North American member institution. Note: (history of) treatment on a COG therapeutic trial is not required.
  • * Patients must be diagnosed at \< 20 years of age at the time of GCT diagnosis. Study participants will be followed over time in the survivorship study so there is no maximum age for participation.
  • * Participants must be able to complete study related documents in English or Spanish.
  • * All patients and/or their parents or legal guardians must provide informed consent. Assent will be obtained for participants between the ages of 8-17 years.
  • * All institutional, FDA, and NCI requirements for human studies must be met.
  • * Participants from AEPI10N1 who did not consent to future contact. Patients who do not meet the eligibility criteria described above or cannot complete study materials in English or Spanish

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Children's Oncology Group,

Jenny Poynter, PhD, PRINCIPAL_INVESTIGATOR, Children's Oncology Group

Study Record Dates

2027-06-30